Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (formerly ChromaDex Corporation; Ticker: NAGE)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A global bioscience company focused on healthy aging, primarily through the development and commercialization of Niagen® (nicotinamide riboside chloride), an NAD+ precursor. The company operates through Consumer Products (Tru Niagen®), Ingredients (food-grade and pharmaceutical-grade Niagen®), and a non-revenue-generating Pharmaceuticals segment. The Analytical Reference Standards and Services segment was sold in February 2026.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $129.4 million | $99.6 million | +30% |
| Gross Profit | $83.2 million | $61.6 million | +35% |
| Gross Margin | 64.3% | 61.8% | +250 bps |
| Net Income | $17.4 million | $8.6 million | +103% |
| Diluted EPS | $0.20 | $0.11 | +82% |
| Operating Cash Flow | $13.5 million | $12.1 million | +12% |
| Cash & Equivalents | $64.8 million | $44.7 million | +45% |
| Debt | $0 (No borrowings) | $0 | - |
Segment Performance (2025):
- Consumer Products: $97.7 million (75% of total sales), driven by e-commerce growth.
- Ingredients: $28.7 million (22% of total sales), driven by food-grade and pharmaceutical-grade Niagen®.
- Analytical Reference Standards: $3.1 million (2% of total sales); assets held for sale.
Material Changes vs. Prior Period
- Revenue Growth: Total net sales increased 30% year-over-year. Consumer Products grew 27% and Ingredients grew 45%.
- Profitability: Net income more than doubled to $17.4 million, aided by a $2.0 million gain on the settlement of royalty obligations with Queen's University Belfast and improved operating leverage.
- Expense Management: Sales and marketing expenses increased 20% but decreased as a percentage of net sales (27% vs. 30% in 2024). General and administrative expenses rose 47% due to higher employee costs and the absence of a $3.5 million royalty reversal recorded in 2024.
- Balance Sheet: Inventory increased significantly to $20.4 million (from $9.2 million) to support business growth. Cash reserves grew to $64.8 million.
- Strategic Divestiture: Committed to sell the Analytical Reference Standards and Services segment for approximately $6.0 million (closed Feb 2026).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook:
- Management believes current cash resources and operating cash flow are sufficient to fund operations for at least the next 12 months.
- Continued focus on expanding pharmaceutical-grade Niagen® distribution via 503B outsourcing facilities.
- Share repurchase program authorized for up to $10 million; $0.3 million utilized in Q4 2025.
Unusual Items:
- Gain on Settlement: Recognized a $2.0 million gain from settling royalty obligations with Queen's University Belfast.
- ERTC Disallowance: Recorded a $0.2 million expense due to partial disallowance of Employee Retention Tax Credits by the IRS.
Key Risks & Contingencies:
- Supply Chain Concentration: Reliance on a single supplier, W.R. Grace & Co.-Conn., for food-grade NRC (nicotinamide riboside chloride). The supply agreement runs through 2029.
- Legal Proceedings:
- Elysium Health: A $9.2 million judgment (plus interest, estimated total ~$10.4 million) was entered against the company in a Delaware patent infringement case. The company has appealed; no accrual recorded as the outcome is uncertain.
- FDA Litigation: Filed a lawsuit in Feb 2026 challenging the FDA's regulatory status of NMN (nicotinamide mononucleotide) as a dietary ingredient.
- Product Recall: A retail partner in Asia initiated a recall of Tru Niagen Immune Daily Defense in Dec 2025; potential damages are being quantified.
- Regulatory: Risks related to FDA enforcement regarding dietary supplement claims and the status of NAD+ precursors.
Investor Verification Checklist
- Legal Exposure: Verify the status of the appeal regarding the ~$10.4 million Elysium Health judgment and the potential impact on future cash flows.
- Supply Chain Security: Confirm the stability of the exclusive supply agreement with W.R. Grace and the terms of the 2029 renewal.
- Regulatory Landscape: Monitor the outcome of the FDA lawsuit regarding NMN and its potential impact on competitive dynamics.
- Inventory Valuation: Assess the $20.4 million inventory balance against sales velocity, particularly given the recent product recall in Asia.
- Segment Transition: Confirm the final closing details and financial impact of the sale of the Analytical Reference Standards segment.